Dasatinib reversibly disrupts T cell motility and activation in lymph nodes
{{output}}
The tyrosine kinase inhibitor dasatinib is prescribed as a first-line treatment for Philadelphia chromosome-positive leukemias and is increasingly used in other clinical settings. While dasatinib is effective and generally well tolerated, patients often experi... ...
